title: Front line treatment of elderly multiple myeloma in the era of novel agents.
abstract: Melphalan combined with prednisone (MP) has long been the historical treatment of reference for a large proportion of elderly myeloma (MM) patients ineligible for autologous stem cell transplantation, and is still the backbone of new regimens that include the new era of novel agents. Melphalan-prednisone-thalidomide (MPT) and melphalan-prednisone-bortezomib (Velcade((R)), MPV), proved superior to MP, currently appear to be the treatments of choice for this population. In the near future melphalan-prednisone-lenalidomide (Revlimid((R)), MPR) will also provide a third therapeutic option (MPT, MPV, and MPR), in elderly multiple myeloma, eventually. These options could lead to more personalized treatment approaches, based on patient comorbidities, as the three novel agents have somewhat different toxicity profiles. Dexamethasone-based regimen is another option and questions regarding the relative efficacy of melphalan-based versus low-dose dexamethasone-based regimens will require randomized phase III trials. More intensive approaches with new drug combinations or with the incorporation of polyethylene glycolated (PEGylated) liposomal doxorubicin will also require additional studies. Additionally, the important issue of maintenance treatment needs to be further investigated. These new and emerging therapies offer multiple effective treatment options for MM patients and greatly enhanced treatment strategies for clinicians.
authors.affiliation: Service des Maladies du Sang, Hopital Huriez, CHRU, Lille, France.
authors.forename: Marie-Dominique
authors.initials: MD
authors.lastname: Venon
authors.forename: Aldo M
authors.initials: AM
authors.lastname: Roccaro
authors.forename: Julie
authors.initials: J
authors.lastname: Gay
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Moreau
authors.forename: Remy
authors.initials: R
authors.lastname: Dulery
authors.forename: Thierry
authors.initials: T
authors.lastname: Facon
authors.forename: Irene M
authors.initials: IM
authors.lastname: Ghobrial
authors.forename: Xavier
authors.initials: X
authors.lastname: Leleu
references.citation: Blood. 2006 Feb 15;107(4):1292-8
references.pmid: 16174762
references.citation: Blood. 2008 Apr 15;111(8):4039-47
references.pmid: 18268097
references.citation: Leuk Lymphoma. 2003 Sep;44(9):1545-8
references.pmid: 14565658
references.citation: N Engl J Med. 2006 Mar 9;354(10):1021-30
references.pmid: 16525139
references.citation: Blood. 2002 May 1;99(9):3163-8
references.pmid: 11964279
references.citation: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references.pmid: 15661684
references.citation: J Clin Oncol. 1998 Feb;16(2):593-602
references.pmid: 9469347
references.citation: J Clin Oncol. 1998 Dec;16(12):3832-42
references.pmid: 9850028
references.citation: J Clin Oncol. 2006 Sep 20;24(27):4507-14
references.pmid: 16940275
references.citation: J Clin Oncol. 2002 Nov 1;20(21):4319-23
references.pmid: 12409330
references.citation: Blood. 1992 Aug 15;80(4):887-90
references.pmid: 1498331
references.citation: Crit Rev Oncol Hematol. 2005 Dec;56(3):397-406
references.pmid: 16310372
references.citation: N Engl J Med. 1996 Jul 11;335(2):91-7
references.pmid: 8649495
references.citation: Eur J Haematol. 2005 Nov;75(5):370-5
references.pmid: 16191085
references.citation: Br J Haematol. 2005 Jun;129(6):763-70
references.pmid: 15953002
references.citation: N Engl J Med. 2003 Jun 26;348(26):2609-17
references.pmid: 12826635
references.citation: JAMA. 1969 Jun 2;208(9):1680-5
references.pmid: 5818682
references.citation: N Engl J Med. 2005 Jun 16;352(24):2487-98
references.pmid: 15958804
references.citation: Blood. 2001 Jul 15;98(2):492-4
references.pmid: 11435324
references.citation: Haematologica. 2006 Jul;91(7):968-71
references.pmid: 16757414
references.citation: Blood. 2008 Oct 15;112(8):3107-14
references.pmid: 18505783
references.citation: Clin Ther. 2003 Feb;25(2):342-95
references.pmid: 12749503
references.citation: N Engl J Med. 2004 Oct 28;351(18):1860-73
references.pmid: 15509819
references.citation: Br J Haematol. 2004 Oct;127(2):159-64
references.pmid: 15461621
references.citation: Blood. 1996 Apr 1;87(7):2675-82
references.pmid: 8639883
references.citation: Br J Cancer. 1988 Jan;57(1):94-9
references.pmid: 3279997
references.citation: Cancer. 2008 Apr 1;112(7):1522-8
references.pmid: 18278812
references.citation: Blood. 2008 Feb 15;111(4):1805-10
references.pmid: 17875806
references.citation: Cancer. 1975 Oct;36(4):1192-201
references.pmid: 1175123
references.citation: Blood. 2005 Dec 15;106(13):4050-3
references.pmid: 16118317
references.citation: Biochem Pharmacol. 2000 Jun 15;59(12):1489-99
references.pmid: 10799645
references.citation: J Clin Oncol. 2006 Feb 20;24(6):937-44
references.pmid: 16418495
references.citation: Ann N Y Acad Sci. 2007 Nov;1117:209-57
references.pmid: 18056045
references.citation: Br J Haematol. 2001 Sep;114(3):600-7
references.pmid: 11552985
references.citation: Bone Marrow Transplant. 2006 Feb;37(4):367-72
references.pmid: 16415893
references.citation: J Clin Oncol. 2007 Jun 10;25(17):2464-72
references.pmid: 17515569
references.citation: Lancet. 2006 Mar 11;367(9513):825-31
references.pmid: 16530576
references.citation: N Engl J Med. 1997 Jun 5;336(23):1657-64
references.pmid: 9171069
references.citation: Blood. 2006 Nov 15;108(10):3289-94
references.pmid: 16873668
references.citation: Blood. 2002 Nov 1;100(9):3063-7
references.pmid: 12384400
references.citation: Blood. 2001 Sep 1;98(5):1614-5
references.pmid: 11520815
references.citation: J Clin Oncol. 2004 Aug 15;22(16):3212-4
references.pmid: 15249587
references.citation: J Clin Oncol. 2006 Jan 20;24(3):431-6
references.pmid: 16365178
references.citation: Ann Oncol. 2008 Jun;19 Suppl 4:iv54-5
references.pmid: 18519405
references.citation: Ann Oncol. 2005 Apr;16(4):634-9
references.pmid: 15741226
references.citation: Mayo Clin Proc. 2004 Jul;79(7):875-82
references.pmid: 15244383
references.citation: Ann Oncol. 2000 Nov;11(11):1427-36
references.pmid: 11142483
references.citation: Clin Adv Hematol Oncol. 2004 Apr;2(4):233-41
references.pmid: 16163188
references.citation: Neurology. 2004 Jun 22;62(12):2291-3
references.pmid: 15210898
references.citation: Blood. 2003 Mar 15;101(6):2377-80
references.pmid: 12424198
references.citation: Lancet. 2007 Oct 6;370(9594):1209-18
references.pmid: 17920916
references.citation: Mayo Clin Proc. 2006 Aug;81(8):1047-53
references.pmid: 16901028
references.citation: Leukemia. 2008 Feb;22(2):414-23
references.pmid: 18094721
references.citation: N Engl J Med. 1999 Nov 18;341(21):1565-71
references.pmid: 10564685
references.citation: Bone Marrow Transplant. 2003 Sep;32(6):587-92
references.pmid: 12953131
references.citation: Br J Haematol. 2007 Jan;136(2):203-11
references.pmid: 17233817
references.citation: Eur J Cancer. 2007 Jan;43(2):258-70
references.pmid: 17182241
references.citation: Haematologica. 2008 Apr;93(4):560-5
references.pmid: 18322252
references.citation: Cancer. 2008 Apr 15;112(8):1754-64
references.pmid: 18300230
references.citation: Best Pract Res Clin Haematol. 2007 Dec;20(4):817-35
references.pmid: 18070721
references.citation: Blood. 2002 Jun 15;99(12):4525-30
references.pmid: 12036884
references.citation: Haematologica. 2001 Apr;86(4):399-403
references.pmid: 11325646
references.citation: Haematologica. 2006 Jan;91(1):133-6
references.pmid: 16434383
references.citation: Blood. 2008 Apr 15;111(8):3968-77
references.pmid: 18245666
references.citation: Cancer. 2003 Oct 15;98(8):1735-44
references.pmid: 14534891
references.citation: Blood. 2006 Oct 1;108(7):2165-72
references.pmid: 16772605
references.citation: Cancer. 2005 Oct 1;104(7):1428-33
references.pmid: 16116606
references.citation: Leuk Lymphoma. 2002 Sep;43(9):1777-82
references.pmid: 12685831
references.citation: Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 May;103(5):599-609
references.pmid: 17291793
references.citation: J Dent Res. 2007 Nov;86(11):1022-33
references.pmid: 17959891
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6279s-6284s
references.pmid: 17062714
references.citation: Blood. 2002 Aug 15;100(4):1168-71
references.pmid: 12149193
references.citation: N Engl J Med. 2006 May 11;354(19):2079-80
references.pmid: 16687729
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8580-7
references.pmid: 16314620
references.citation: Ann Hematol. 2003 Oct;82(10):654-9
references.pmid: 12845480
references.citation: Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):801-4
references.pmid: 7683017
references.citation: N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102
references.pmid: 16000365